SE8801426D0 - METHOD AND METHOD OF BLOOD TREATMENT - Google Patents

METHOD AND METHOD OF BLOOD TREATMENT

Info

Publication number
SE8801426D0
SE8801426D0 SE8801426A SE8801426A SE8801426D0 SE 8801426 D0 SE8801426 D0 SE 8801426D0 SE 8801426 A SE8801426 A SE 8801426A SE 8801426 A SE8801426 A SE 8801426A SE 8801426 D0 SE8801426 D0 SE 8801426D0
Authority
SE
Sweden
Prior art keywords
blood
mitogen
blood sample
vitro
bodies
Prior art date
Application number
SE8801426A
Other languages
Swedish (sv)
Inventor
Ulf Rothman
Original Assignee
Ulf Rothman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ulf Rothman filed Critical Ulf Rothman
Priority to SE8801426A priority Critical patent/SE8801426D0/en
Publication of SE8801426D0 publication Critical patent/SE8801426D0/en
Priority to PCT/SE1989/000208 priority patent/WO1989009619A1/en
Priority to AU34206/89A priority patent/AU632999B2/en
Priority to KR1019890702371A priority patent/KR900700131A/en
Priority to JP1504245A priority patent/JPH03503640A/en
Priority to EP19890904646 priority patent/EP0406317A1/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C45/00—Injection moulding, i.e. forcing the required volume of moulding material through a nozzle into a closed mould; Apparatus therefor
    • B29C45/17—Component parts, details or accessories; Auxiliary operations
    • B29C45/64—Mould opening, closing or clamping devices
    • B29C45/66—Mould opening, closing or clamping devices mechanical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C45/00—Injection moulding, i.e. forcing the required volume of moulding material through a nozzle into a closed mould; Apparatus therefor
    • B29C45/17—Component parts, details or accessories; Auxiliary operations
    • B29C45/64—Mould opening, closing or clamping devices
    • B29C45/66—Mould opening, closing or clamping devices mechanical
    • B29C2045/667—Cam drive for mould closing or clamping

Abstract

An immuno-stimulating blood preparation, suitable for e.g. tumor therapy, is prepared by incubating a cell-containing blood sample, especially whole blood, taken from a specific individual, with a mitogen in vitro to produce a blood preparation designed to be re-administered to the same individual. The method comprises the further step of removing anti-bodies, which are specific for the mitogen used, from the blood sample before the incubation with the mitogen in vitro. The anti-bodies are preferably removed by contacting the blood sample with the corresponding mitogen or its active derivatives or active immobilized forms of the mitogen. Preferred mitogen such as SEA have a strong specificity for MHC II on accessory cells such as monocytes and/or B cells. A blood treatment kit for carrying out the method comprises at least one blood container having a blood sample inlet and a blood sample outlet, separation means provided in said outlet, and means for contacting said blood sample with at least one agent having mitogenic activity in the blood container. The separation means are preferably capable of separating the mitogen from the blood sample to make the treated blood sample substantially free from mitogenic activity.
SE8801426A 1988-04-15 1988-04-15 METHOD AND METHOD OF BLOOD TREATMENT SE8801426D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
SE8801426A SE8801426D0 (en) 1988-04-15 1988-04-15 METHOD AND METHOD OF BLOOD TREATMENT
PCT/SE1989/000208 WO1989009619A1 (en) 1988-04-15 1989-04-14 Method and means for immuno-stimulating blood treatment with mitogen
AU34206/89A AU632999B2 (en) 1988-04-15 1989-04-14 Method and means for immuno-stimulating blood treatment with a mitogen
KR1019890702371A KR900700131A (en) 1988-04-15 1989-04-14 Method and apparatus for immunostimulatory blood treatment by mitosis
JP1504245A JPH03503640A (en) 1988-04-15 1989-04-14 Methods and means of blood processing
EP19890904646 EP0406317A1 (en) 1988-04-15 1989-04-14 Method and means for immuno-stimulating blood treatment with mitogen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8801426A SE8801426D0 (en) 1988-04-15 1988-04-15 METHOD AND METHOD OF BLOOD TREATMENT

Publications (1)

Publication Number Publication Date
SE8801426D0 true SE8801426D0 (en) 1988-04-15

Family

ID=20372041

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8801426A SE8801426D0 (en) 1988-04-15 1988-04-15 METHOD AND METHOD OF BLOOD TREATMENT

Country Status (6)

Country Link
EP (1) EP0406317A1 (en)
JP (1) JPH03503640A (en)
KR (1) KR900700131A (en)
AU (1) AU632999B2 (en)
SE (1) SE8801426D0 (en)
WO (1) WO1989009619A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8903100D0 (en) * 1989-09-20 1989-09-20 Pharmacia Ab NEW PHARMACEUTICAL AGENT
US6042837A (en) * 1989-09-20 2000-03-28 Kalland; Terje Methods of staphylococcal enterotoxin directed cell-mediated cytotoxicity (SDCC)
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
DE69133068T2 (en) * 1990-01-17 2003-03-13 David S Terman TUMOR DESTROYING EFFECTS OF ENTEROTOXINS AND RELATED COMPOUNDS
CA2157379A1 (en) * 1993-03-02 1994-09-15 David S. Terman Method of cancer treatment
ES2236719T3 (en) * 1994-11-17 2005-07-16 University Of South Florida METHOD TO MANUFACTURE A MEDICINAL PRODUCT FOR THE TREATMENT OF SECONDARY IMMUNODEFICIENCY.
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
AU2002232560A1 (en) 2000-10-27 2002-05-06 Immuno-Rx, Inc Vaccine immunotherapy for immune suppressed patients
DK2234642T3 (en) 2007-11-28 2018-01-08 Irx Therapeutics Inc PROCEDURE FOR INCREASING AN IMMUNOLOGICAL EFFECT
CA3017298C (en) 2009-05-15 2021-09-28 Irx Therapeutics, Inc. Compositions comprising primary cell-derived biologics for enhancing immune responses in patients
JP5889797B2 (en) 2009-12-08 2016-03-22 アイアールエックス セラピューティクス， インコーポレイテッド Methods to reverse the immunosuppression of Langerhans cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU570911B2 (en) * 1981-11-06 1988-03-31 Baylor College Of Medicine Immunoadsorbent based on immobilized protein a and its use
CA1204667A (en) * 1982-10-04 1986-05-20 Masashi Kodama Blood treating material
JPS60501558A (en) * 1983-06-13 1985-09-19 マリエッテ、コンサルタンツ、リミテッド Method for treating interferon-sensitive diseases and method and apparatus for producing γ-interferon-containing preparations
US4551435A (en) * 1983-08-24 1985-11-05 Immunicon, Inc. Selective removal of immunospecifically recognizable substances from solution
DE3483252D1 (en) * 1983-12-05 1990-10-25 Asahi Chemical Ind METHOD FOR THE INDUCTION OF ANTITUM IMMUNOCYTES, METHOD FOR THE PRODUCTION OF ANTITUM IMMUNOCYTES AND ANTITUM IMMUNOCYTS PRODUCED BY THE METHOD.
NO175594C (en) * 1988-01-25 1994-11-02 American Cyanamid Co Method for isolating heparin-binding brain mitogen
EP0400077A4 (en) * 1988-02-12 1990-12-27 The Regents Of The University Of California Use of synthetic peptides to generate and manipulate cellular immunity

Also Published As

Publication number Publication date
EP0406317A1 (en) 1991-01-09
WO1989009619A1 (en) 1989-10-19
AU3420689A (en) 1989-11-03
AU632999B2 (en) 1993-01-21
KR900700131A (en) 1990-08-11
JPH03503640A (en) 1991-08-15

Similar Documents

Publication Publication Date Title
Metcalf et al. Formation of eosinophilic‐like granulocytic colonies by mouse bone marrow cells in vitro
US4444887A (en) Process for making human antibody producing B-lymphocytes
RAPOPORT Dog thyroid cells in monolayer tissue culture: adenosine 3', 5'-cyclic monophosphate response to thyrotropic hormone
Zanetta et al. The presence of 2′, 3′‐cyclic AMP 3′‐phosphohydrolase in glial cells in tissue culture
Sugiura et al. Wheat germ agglutinin-positive cells in a stem cell-enriched fraction of mouse bone marrow have potent natural suppressor activity.
US4390623A (en) Serum-free and mitogen-free T-cell growth factor and process for making same
Goldschneider et al. Induction of terminal deoxynucleotidyl transferase and Lyt antigens with thymosin: identification of multiple subsets of prothymocytes in mouse bone marrow and spleen.
AU9058091A (en) Preparation of nucleic acid samples
CA2259984A1 (en) Precise efficacy assay methods for active agents including chemotherapeutic agents
WO1996023060B1 (en) Method for isolating dendritic cells
Vallee et al. Purification of microtubules and microtubule-associated proteins from sea urchin eggs and cultured mammalian cells using taxol, and use of exogenous taxol-stabilized brain microtubules for purifying microtubule-associated proteins
SE8801426D0 (en) METHOD AND METHOD OF BLOOD TREATMENT
ES2132063T3 (en) PROCEDURE FOR THE CAPTURE AND RECOVERY OF CELLS.
DE3886254D1 (en) Apparatus for the treatment of biological samples and treatment methods with the apparatus.
Stasny et al. The effect of sonic oscillation on the structure and function of beef heart mitochondria
Kahan Isolation of a soluble transplantation antigen
Pope et al. Two distinct populations of suppressor cells in the spleens of mice bearing methylcholanthrene-induced tumors
Altman et al. Natural cell-mediated cytotoxicity in guinea pigs: properties and specificity of natural killer cells
Basch et al. Thymopoietin-induced acquisition of responsiveness to T cell mitogens
ES8501630A1 (en) In vitro diagnostic methods using monoclonal antibodies against connective tissue proteins.
ATE76751T1 (en) PROCEDURE FOR ISOLATION OF BLOOD COAGULATION FACTOR IX.
Moskalewski et al. Presence of egg antigen in immature oocytes and preimplantation embryos
Tsang et al. Modulation of T-and B-lymphocyte functions by isoprinosine in homosexual subjects with prodromata and in patients with acquired immune deficiency syndrome (AIDS)
Lundgren et al. In vitro cytotoxicity by human lymphocytes from individuals immunized against histocompatibility antigens. II. Relation to HL-A incompatibility between effector and target cells
FI881122A (en) Method for isolating basement membrane proteins from human and animal tissues